Reddit Posts
Capricor - FDA Insight and New Headquarter Long Term Lease
NKTX Nkarta, Inc. - Conviction Play for Autoimmune Treatment
CAPR Capricor Therapeutics stock
$VNDA - DD - Why it will likely be moving up throughout the week starting Monday PM
$VNDA - Why it will be gaining significantly starting Monday PM
$VNDA - Why it will be a big mover starting Monday PM
$GANX — The Most Asymmetric Setup I’ve Ever Seen (And the Clock Is Ticking)
How I traded my way up to six figures without any knowledge or experience.
How I traded my way up to six figures without any knowledge or experience.
Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days
CAPR delivered how many people on here were in on it?
Capricor Therapeutics - Dream Setup $CAPR - Long Call
CAPR short squeeze candidate. Has all the makings but no one is paying attention…
2026 - will the uk or us see a decline in the equity market
CAPR - Phase 3 Topline Results Bet - $325k
$CAPR Follow-Up After about a 7% gain today and looking to have solid SS potential coming up in Q4
$CAPR might squeeze soon as MD drug regains FDA support after resubmission for approval
Vinnay Prassad OUT at HHS +++ for Deramiocel approval (CAPR)
Lookout for Precigen (PGEN) and Capricor (CAPR)
Bought 5000 CAPR yesterday. Took profits today and bought 5000 more. Many predicting approval at the end of July. Sky is the limit.
CAPR: Regulatory Chess, Institutional Tension, and One Hell of a Setup
My $1.6M bet on a micro-cap biotech with a real FDA shot. CAPR DD
$CAPR, $BDMD, $ORKT, $SST, $LWLG Squeezefinder AI watchlist top picks 9june2025, NFA. LWLG is on there again, so something is going on with that stock. SST has the most to gain OR lose, be careful!
🚨 CAPR It’s happening!!! This Setup Is Getting Wild 🚨
🚨 We’re Close to Forcing a Cover — Possibly Today or Monday $CAPR🚨
🚨 They’re Trying to Hold It Down—But the Clock Is Ticking 🚨
🚨 Wall Street is Betting Against Kids with Muscular Dystrophy 🚨
🚨 Wall Street is Betting Against Kids with Muscular Dystrophy 🚨
🚨 Wall Street is Betting Against Kids with Muscular Dystrophy 🚨
Who’s gonna make the Russell 2000 prelim list on May 23, 2025?
Diversified biotech short portfolio - completely tweaked on naked short calls (-20 500$)
7 Undervalued Penny Stocks With Major Upside
Biotechs With Potential Catalysts This Week: $SPPI $VSTM $APRE $CAPR $CFMS
My Top Biotech Plays to get your Account Positive by the Years End
$CAPR - stock is hovering around $4 bucks. They just signed a worldwide licensing deal with John’s Hopkins University for their exosome technology. They’re leaders in DMD treatment and and future COVID vaccines. This thing should be trading at $12 bucks minimum right now. $100+ in coming years. BULL
Mentions
$CAPR on duchenne muscular approval in August with a cure able to deliver $2-3 billion in peak revenues or more.
Buying at the top also is not wise - Everyone said my last two picks were going to $0 - Lionsgate had No IP they said, now up to 5 year highs post-split, and CAPR was also dead according to Martin S. and here we are at 500% returns. Anytime I post on here, everyone hates the play, then 1 year later, they comment back on their hate. Maybe I won't go 3/3 but I believe we are higher likely to go up vs. down here. AND low debt is wonderful.
Exactly, fake news as usual people always hate my calls, which so far have returned 500% and 300% (CAPR & LION) I love the hate keep bringing it on.
SLS - it’s not too late OMER - has EMA decision very soon on Yartemlea. Plus theyre actively looking for an EU partnership for the drug. They also have a $2.1 billion deal with NOVO for another drug of there’s that finished up phase 2 CAPR - They have an FDA approval decision for Deramiocel in August. They’re in a legal battle with Nippon over the drug (had a partnership agreement together, but CAPR & Nippon both claim there was pricing flaws in the signed agreement), still ongoing, but I think the stock has been oversold from the legal situation GRRR - a smaller AI company ($550 million market cap) that made just over $100 million revenue in 2025, current revenue guidance from mgmt is $160-$200 million for 2026. On the earnings call this week the CEO verbatim said the $200 million top end was “ultra conservative” and could be revised upwards later this year. On the same call, the CEO said he’s aiming for $500 million revenue for 2027. This stock should be double right now, and it has started to take off this week
CAPR as the standard cure choice for Duchenne
Speculative plays with huge upside: CAPR, SLS, GRRR Biotech growth stock: OMER
Sold a bunch of cash secured puts. I'm the proud new owner of 700K of CAPR lol. Here's to August approval!
My biggest long position (CAPR) staved off collapse in it's earning call today. I live to fight another day!
CAPR I think the market has overreacted to their lawsuit against NS. The details CAPR provided on their press release do not look good for Nippon, and Nippons official response to the lawsuit seems to convey that they really want to settle this.
Thank you! No I didn’t anticipate that. However, if it’s true that Nippon was unwilling to compromise on drug pricing so that Medicare and Medicaid patients would be able to easily get this drug, then it was necessary for CAPR to do this. If not, it would have commercially failed Deramiocel. The other good news is that this lawsuit should move quickly due to the upcoming PDUFA in August. I think this will be settled in 1-2 months. If it works out for CAPR, and they gain total control of Deramiocel distribution, then that will be a huge benefit for them. They would also have the ability to make a new partnership deal if they’d like
#TLDR --- Ticker: CAPR Direction: Up 🚀 Prognosis: Buy shares or long-dated calls targeting $60+ by late Summer 2026 (PT $100 if broad label approval) Catalyst: FDA Approval decision on August 22, 2026 for their drug Deramiocel (Duchennes Muscular Dystrophy) Source of Hopium: Solid Phase 3 data, $300M in cash (no dilution), 19% short interest, and rumors from a StockTwits guy named "LineBacker04"
Continuing to add to my positions in CAPR, OMER, and SLS today
FDA decision is a binary event, but I think any researcher/scientist would acknowledge that some research designs and data are better than others. The biggest unknown was leading up to CAPR revealing top line data results for HOPE-3. That was a true unknown, and also why the stock shot up over 500% when Deramiocel successfully hit the primary and secondary end points. Now we know much more about the phase 3 results. CAPRs phase 3 study, HOPE-3, has very strong data and has a rigorous design. Look up their HOPE-3 data presentation at the MDA conference back in March, which revealed much more detail about the secondary end points of the study
I agree, biotech can be very volatile and high risk. I have a very high amount of confidence in CAPR getting FDA approval for Deramiocel, but the chances of a CRL are not 0%. If the FDA rejects Deramiocel, CAPR will crash hard (over 80% imo). I’ve invested as much as I’m willing to lose
#TLDR --- **Ticker:** CAPR **Direction:** Up 🚀 (Expecting a 2x to 3x bagger) **Prognosis:** Buy shares and hold through the August 22nd, 2026 FDA decision ($60 conservative PT, $100+ aggressive PT) **Catalyst:** FDA Approval for Deramiocel, massive label expansion potential, and an $80M milestone payment. **Source of Trust:** "Rigorous" Phase 3 data, 19% short interest fuel, and a StockTwits guy named LineBacker04. **Ape Translation:** Biotech company cures kids' muscles, has cash through 2027 so no dilution, gets FDA stamp of approval, and rockets to the moon while squeezing the shorts.
Then for research purposes, how do you feel about CAPR, OMER, and SLS?
I definitely understand that, biotechs have a lot of inherent risk. Even if a drug is FDA approved, it could be “sell the news”. However, I feel strongly about CAPR because of their Hope-3 study data, which they fully presented at the 2026 MDA Clinical and Scientific Conference this past March. The study had a rigorous design, and the data looks strong. I don’t think it will be a “sell the news” situation because CAPR has fairly high short interest right now (over 20%), they will get a PRV from the FDA if it’s approved, and they will get an $80 milestone payment from Nippon if it’s approved. I’m planning to do a large post about CAPR here soon with more details about their overall situation, and my predictions for where I think the share price will go by the end of 2026, and into 2027. If you dedicate a piece of your portfolio to high-risk high reward stock, then I encourage you to look into CAPR
CAPR - this is my favorite biotech stock right now. If Dr. Houman Hemmati is appointed the new head of CBER, I there will be small increase (~10%) in the very short term (new CBER appointment should be end of April as Prasad leaves). Dr. Hemmati formerly worked at CAPR. If it’s someone else, there could be a small decline in CAPR stock. But that will be a great entry point in my opinion. Their drug Deramiocel is up for FDA approval in August. If it’s gets approved, I think this stock will trade around at least $50 per share, with a high range over $60 per share.
Put that into CAPR, and I think you’ll get $10 by August at the latest, and if you’re lucky, maybe even $15!
Loading up on non-impacted companies such as Lionsgate, SLG, CAPR, etc. Rather bet on near certain binary events for a 30-50% upside in 12-18 months.
No one talking about CAPR hmm
NBIS, APLD -> NBIS as a 'full-stack' ai infra play, APLD as a low-mcap well-managed infra gamble CAPR -> it's a binary play but IF they get the FED approval, the price will skyrocket.
How did CAPR go for him?
CAPR - FDA approval is imminent for lead drug, exosomes trial update and many more milestones 2026. Potential Buyout candidate. Biostocks is bound for a rebound while I think the market in general will underperform
CAPR - because they have phase 3 success and are months away from FDA approval. Off-brand use of their drug can slow down miocarditis, the only proven compound to do so.
I do the same thing. When the stock rises ?X i sell enough to gain back my original investment then hold the rest til I decide to dump them. Its all free shares at that point. My best was CAPR at avg cost of $1.10. Wish I would have bought a whole LOT more. Still have some and buy the dips also.
As a purely subjective observation pharma companies do this even if it’s known ahead of time that the catalyst events are coming. Look at the yearly trend of CAPR for instanc, it is as down on nothing but a lack of news until it mooned on good news.
Btw, I also had CAPR on a small list of biotechs I put together reading reddit dd, but forgot about it until after it mooned
He got smoked the other day on live stream and liquidated by his broker on a short position he had open on CAPR. He was back the next day talking about how QCLS is the next thing and how he's going to ask Trump if he can make an exception for him to be CEO of this company lol.
What happened to Martin Shkreli’s live stream? Did he actually lose all his investing money recently shorting CAPR?
Look what happened to Martin shkreli’s professional DD on $CAPR, no one really knows shit lol. I’m doing lotto puts on MLTX for the gambol. 100 cons $10p
lol been holding since 2023, your post literally makes no sense. I’ve posted in this thread months ago about CAPR.
I’m assuming you haven’t watched his apology video apologizing to all his followers for leading them to short CAPR?
While you paper trade and learn options which even if you have the system down will vary stock by stock. I would buy CAPR, they just met phase 3 end points with flying colors so their stem cell based product will get approved at BLA filing. Will take roughly a year for BLA approval, but will happen. On approval should hit similar valuation as MESO.
I only know bc I bought puts on the stock that got him, $CAPR. But I bought mine AFTER it mooned, he was betting that it would go from $8 to $2, and it went over $30
https://preview.redd.it/1qs0fqpzqf5g1.jpeg?width=1080&format=pjpg&auto=webp&s=b4ce641e423646433e367f8b126c8bd6fb767058 Biomarker is out anytime in December. I would imagine Monday December 8, or Monday December 15. Positive data will make this run like CAPR (400%)
it still is great fun to open up the port today and see my CAPR position skyrocketed from -50% to +140% due to some bullshit happening this week that I can't even understand. Needless to say my CRWV and NBIS options are in the shitter, but who cares man? It's snowing!
This is something I think of a lot: It truly depends on what you’re holding. Like if you’re heavy in a recently IPO’d AI Data Center company, you could time your entry well and find yourself up 20-30%+ in the matter of days or weeks. However, in that same regard these kind of companies are often: 1) Low volume. 2) Contingent on any market/sector noise (good or bad). 3) Are news heavy, negative press can crush something that’s new and likely not profitable yet. So you can see how that 20-30% gain could flip to being either 0% again, or even down a significant percentage. You can hold onto it, but if you don’t believe in the company fundamentally why diamond hand it? I think taking profit on riskier plays is a good move imo, just understand you will pay more Capital Gains Tax if you hold for less than a year. Also note this: You can take pieces of your profit when you’re satisfied or worried about volatility. Pretend you have 1,000 shares of a long term holding ; let’s say you got TSLA in 2020. Your initial investment was $200,000 because you got 1k shares at $200. It’s now worth $450,000+ since 2020. You could cut your position in half and still have double your initial investment tax included. That’s a dreamy scenario, but the idea is if a stock does well you could trim and still have a meaningful position in the stock. It’s all about risk management in my view. If you’re going to flip a stock you need to be willing to accept a reality where you may and likely will sell far too early, and buy too high. If you’re selling a volatile stock because you’re happy with your gains, you can’t lose sleep over the loss 15-20% because it could have went the other way too. If you buy too high, it’s preferable to have a company you could feasibly hold long term because it’s fundamentally a good stock to own. Sometimes you can manage to sell at the peak and buy at the bottom, but even seasoned investors can mess the timing up because that’s the name of the game. It’s also about where you are financially, where you want to go, and what your overall plan is. There’s absolutely nothing wrong with taking your money and doing a mix of an S&P 500 fund, VOO, Blue-Chip funds, diversified ETF’s, and maybe even some precious metals; and just holding for the long haul. There’s also nothing wrong with snuffing out individual companies you believe may be those 1,000%-3,000% winners. The issue arises when someone wants fast money and/or thinks they cracked a code somewhere. The small-cap stocks can be fun because they may shoot up nearly 400% in a day like CAPR. But like I said, it goes both ways. Holding shares and being patient isn’t the sexy or cinematic way to invest, but compounding and focusing on sticking to your core goals is statistically lucrative long-term. Everyone has their own unique plan, you can make a lot of money doing a blend of short, medium and long term investments. Full profit taking quickly may not be the smartest idea if you are in a company you truly think will succeed, has a runway to higher levels, and fits your risk profile. But with companies that have rocketed 1,000% or more historically, many weren’t always clear winners. It stings to miss some of the big ones, but for a company to accelerate to such levels and not be a penny stock, it requires a unique set of optimal outcomes. In the end I think it’s potentially better to not be rigid in your strategy always if you’re an active trader. Oftentimes, your original plan gets skewed just like how life usually is. You can’t go wrong taking a bit of profit, or cashing out if you’re satisfied. And even crazy high growth stocks can have some beautiful entry points. NVDA has gone up nearly 100% since April, after it dropped almost 30% in the 3 months prior. So even if you missed the immense gains before that, some made a killing just buying the dip on an already world-leading stock. It takes a mix of knowledge, usually experience, timing, a bit of luck and some blessings with a lot of patience to hold a long-term position that 2x’s, 5x’s or 10x’s. You most certainly will miss some huge winners, but the interesting thing is, even massive winners can create low entry’s to make substantial gains. It’s simple in theory to “buy the dip” but in reality it is mentally difficult. When markets tank, sentiment is bad and the news amplifies it. I think the people who make out like bandits the most are the ones that bought when people were the most fearful, and the market was horrid. And after, they waited for it to come back, even if it dipped more initially. I feel like if one could roughly: A) Find what stocks they want to simply hold and not touch unless necessary. B) Find what they don’t mind trimming if up a bit. C) Find what is strictly a flip and taking profit on that by a certain date. D) Set aside capital for buying on dips. They can probably do well long-term. It’s more appealing to some to make a living Day-trading, but most that want generational wealth over riches understands it’s hardly ever optimal compared to doing it the old-fashioned way. The biggest ROI of any Day-Trader is their online course, they invest a bit of time and sap ambitious but misled people of their money and to think the market is easy pickings. I guess my answer would be: You can sell, trim or rebuy stocks and if it’s for the right reasons it’s no problem if you miss some gains. If you’re involved in the market with the idea you’re going to do it for the long haul, proper strategy can yield immense gains if you can stay grounded. You will very likely not go from decent investments to rich in a year unless you take on massive risk. But, put away a little of your salary in the account, invest with intention and attention, you could grow it into enough to make generational wealth.
LOL Shkreli account completely wiped out by $CAPR He also wants you to know that: 1) It’s no big deal (for him) 2) He is glad the account blew up Says the account is no big deal, started with $30k, went to $260k, then zero. He says, he can now focus on his other businesses and endeavors.
Ride CAPR and getting msft jizz all over my face
CAPR got FDA approved somehow
He had a short on CAPR and it gapped up from 6 to the 30s on news.
IRBT CAPR down GD SPY up Daddy like money
IRBT CAPR down GD SPY up Daddy like money
Time to load up on CAPR puts and watch a new generation of bagholders spawn
$CAPR ctb over 750% over $50 epic squeeze
VRCA, CAPR, VIR, LUNG... maybe ABCL, VTYX
CAPR, RKLB, GOOG, AMD, PLTR, and NET have carried my portfolio hard. - CAPR just popped 300% in one day due to good testing results - got in early on RKLB and think it still has 5x to grow. will probably continue accruing! - GOOG seemed underpriced for me for a long-ass time so have been loading up steadily - it feels good to be right - have been long AMD for years & it’s now one of my biggest holdings thanks to the run - PLTR bag holder since the IPO. only have 40% of my shares left (took profits) and can’t believe they’re up nearly 700% - NET has been an amazing stock, up over 140% did pretty well with RDDT and META as well. heavy tech bias has paid off this year 😅 but i’m scared
You know how much Shkreli just got scorched on his CAPR short? See the chart.
I called CAPR and CAVA opportunities for huge rebounds. Now Im calling IONQ and TTD, huge opportunities.
Always invest in companies with MILF CEOs. Example: CAPR is up 400% today
Yesterday, Martin Shkreli was bullying a MILF ceo about his CAPR short. Today, CAPR is up 400%😆 Lesson: never bet against MILFs
CAPR puts tomorrow?
Shkreli posted how he was short $CAPR and wrote a 46 page report on how it will go down since their treatment won't work and the stock was up 500% at some point today. Bro fumbled so bad and probably made some people have massive losses 😂😂 https://x.com/MartinShkreli/status/1992971976294498581?t=jCK8Q0IWDsk98lo2TjM2Sg&s=19
i have CAPR you can all suck me lolollololl
Watching CAPR for a squeeze into close - shorts have been all over this before this morning's news. Also just got a PT increase to $60 from $24: [https://www.investing.com/news/analyst-ratings/capricor-therapeutics-stock-price-target-raised-to-60-from-24-at-hc-wainwright-93CH-4389195](https://www.investing.com/news/analyst-ratings/capricor-therapeutics-stock-price-target-raised-to-60-from-24-at-hc-wainwright-93CH-4389195)
anyone talk about CAPR today holy shit
Long term what you’re thinking is “I hope these idiots all buy so stock can go up so I can sell my bags cause I held through the actually squeeze like an idiot” You shoulda bought CAPR my guy
$CAPR went nuclear, imagine if you had bought shares or even options before that announcement…
I'll answer to what I think could happen in the next three months. In the next week or two pre-data readout, the price could trade in this current range, but I could also see it running up to $5 or $6 in anticipation, especially if there are any leaks. Upon data readout (maybe as early as next Monday), assuming good data, I think the price jumps anywhere from 30% to 200% (look at CAPR today-- that's in phase 3, but the treatable patient population is 50X smaller than for Parkinson's). I really don't know. The market potential is huge, and there are no disease-modifying treatments available, but it is also only finishing phase 1. But I think in the days to follow, I think investors start turning their focus to partnership or buyout figures. So let's say that it settles around $9 in the days following data release. That's a $450M MC. I think $1B or more, either through partnership or acquisition, is likely by March. Many lesser drugs both in clinical trials and pre-clinically have purchased for big sums, so Gain should easily go for $1B in my opinion, especially since they have back-up compounds and a platform that discovered GT-02287 and the other compounds. $1B is \~$20 per share.
Anyone who followed Shkreli into the CAPR short got absolutely destroyed lol
Anyone think CAPR is going to go straight up After hours once they cant halt it
I sold my CAPR stock two days ago 😂 in @ 5.31 out around 6.8
Still great level to establish a position or add to it, IMO. Check out what happened to $CAPR today with a drug that targets a disease with 50X smaller patient population.
Anyone else have this shit pharma stock CAPR, this thing was in the shit hovering $5-6 for months and today it shot up to $40 at open and had a trade hold placed on it but has seemed to settle back to 25ish the past hour. Needless to say my covered call at 12.50 is absolutely blown the fuck out. I am guessing somebody knows something.
https://preview.redd.it/dpiq69lkg05g1.png?width=695&format=png&auto=webp&s=c0e36eeac4ca31e5c445384658a9e920194ea96b CAPR might rise up. I know its already 300%+
CAPR was at 6.36 yesterday's close, hit 40.37 this morning at peak.
Capricorn Therapeutics. CAPR US.
My guess is he shorted CAPR that went from $7-$40 in 10 mins.
He was shorting $CAPR? He ded.
shkreli blew 3m on CAPR short https://preview.redd.it/psupup2rb05g1.png?width=311&format=png&auto=webp&s=466437811d608899c8ab6e9130811baa2f3a857a
Did Martin Shkreli get obliterated by shorting CAPR
Shkreli just got wrecked on his CAPR short. Hope he bankrupted another hedge fund.
What the fuck is CAPR jesus christ
Shkreli is currently down like 500% or so shorting CAPR btw if you want to watch some drama. Halted for news.
$CAPR MOASS incoming 🔥🔥🔥
CAPR HALTED.....this will be interesting
CAPR is a short squeeze.
Shekreli says short CAPR
$CAPR will fail, and in a few days will release crucial news. little short play, down 19%. biotech (shkreli endorsed). [https://x.com/anthonystaj/status/1992972618077528196?s=20](https://x.com/anthonystaj/status/1992972618077528196?s=20)
I’ve been trading with my IRA that is sub $100k. I never use the entire thing for day trading or non-long term investing and actually I have like 20-30% of my account sitting in cash (which is actually is kind of a waste). I never put all my eggs in one basket. Now with this Ai bubble bursting I’m at 99% cash. Also, CAPR has been looking good for a short squeeze.
How confident are you that the upcoming P3 data will hit primary PUL (and key secondary LVEF) stat sig? I rolled most of my VRNA winnings into AVXL options and got burned badly upon CHMP negative opinion. I have a sizeable position in CAPR but now I am thinking if I should exit. If PUL does not hit, CAPR is most likely over. No way Vinay Prasad shows flexibility that Linda hopes the FDA shows as communicated in her last conference call.